Assenagon Asset Management S.A. Lowers Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Assenagon Asset Management S.A. lowered its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 31.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 102,691 shares of the specialty pharmaceutical company's stock after selling 47,897 shares during the quarter. Assenagon Asset Management S.A. owned about 0.32% of Collegium Pharmaceutical worth $3,065,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Rhumbline Advisers grew its stake in Collegium Pharmaceutical by 5.8% during the 4th quarter. Rhumbline Advisers now owns 108,228 shares of the specialty pharmaceutical company's stock valued at $3,101,000 after purchasing an additional 5,920 shares during the last quarter. Sanctuary Advisors LLC increased its holdings in Collegium Pharmaceutical by 5.3% in the 4th quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company's stock worth $542,000 after buying an additional 952 shares during the period. Versor Investments LP raised its position in Collegium Pharmaceutical by 36.2% during the 4th quarter. Versor Investments LP now owns 19,582 shares of the specialty pharmaceutical company's stock worth $561,000 after buying an additional 5,200 shares during the last quarter. Aigen Investment Management LP acquired a new stake in Collegium Pharmaceutical during the 4th quarter valued at approximately $230,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter worth $2,432,000.

Collegium Pharmaceutical Price Performance

COLL traded up $0.10 during trading on Wednesday, reaching $29.54. The company's stock had a trading volume of 17,815 shares, compared to its average volume of 413,097. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 3.30. The firm has a fifty day simple moving average of $28.33 and a two-hundred day simple moving average of $29.55. The company has a market cap of $948.96 million, a price-to-earnings ratio of 24.20 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). The firm had revenue of $177.76 million for the quarter, compared to analysts' expectations of $174.96 million. Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The company's quarterly revenue was up 22.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.45 earnings per share. As a group, analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, Director John Gordon Freund sold 6,601 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $30.62, for a total value of $202,122.62. Following the transaction, the director now directly owns 70,658 shares of the company's stock, valued at $2,163,547.96. This trade represents a 8.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.51% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on COLL shares. Wall Street Zen downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. Needham & Company LLC reiterated a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.75.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.